US3274063A - Cosmetic cream - Google Patents

Cosmetic cream Download PDF

Info

Publication number
US3274063A
US3274063A US118495A US11849561A US3274063A US 3274063 A US3274063 A US 3274063A US 118495 A US118495 A US 118495A US 11849561 A US11849561 A US 11849561A US 3274063 A US3274063 A US 3274063A
Authority
US
United States
Prior art keywords
cosmetic
magnesium
cream
magnesium aspartate
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US118495A
Inventor
Nieper Hans Alfred
Escherich Georg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MARBERT KOSMETIK FA
MARBERT-KOSMETIK Firma
Original Assignee
MARBERT KOSMETIK FA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MARBERT KOSMETIK FA filed Critical MARBERT KOSMETIK FA
Application granted granted Critical
Publication of US3274063A publication Critical patent/US3274063A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • Cosmetic creams usually comprise emulsion systems of the oil-in-water, or water-in-oil type, or combinations thereof. They are used, for instance, as cold creams or vanishing creams, for smoothing and softening the skin.
  • magnesium aspartate also known as magnesium asparaginate
  • the properties of the cream are considerably improved as far as the effect on the skin is concerned.
  • the skin becomes much softer and smoother than when ordinary cosmetic creams are used.
  • a cosmetic cream in accordance with the invention includes about 0.05 to 10 percent by weight of magnesium aspartate.
  • magnesium in form of said salt is only slightly dissociated in the blood and body liquids, passes easily through the cell walls, and then readily exerts its particular effects inside the cell.
  • the effect of intracellular magnesium consists in an activation of the metabolism ferments of thee esterase type. Such activation improves the growth of the basal layer of the epidermis and produces an increased bonding of intracellular water, increasing the size and tension of the cells.
  • the magnesium salt of glutamic acid which, like aspartic acid, is a dicarboxylic amino acid, does not show the beneficial effect of the magnesium aspartate.
  • the classic model for epithelial tissue is the monkey kidney cell monolayer in cultivation flasks.
  • sterile rhesus kidney cortex tissue treated by Rapaport-trypsination, or hela cells were suspended 1:400 in a culture medium.
  • A's culture medium, a lactalbumin hydrolysate 0.5% in Hanks salt solution, 10% calf serum added was used.
  • test flasks were filled with 90 ml. of the cell containing medium; after 7 days, the culture was treated with 0.2% trypsin solution and then centrifuged. The obtained cell quantity was measure-d in milliliters.
  • the following table gives the results:
  • mag* nesium aspartate is its low cost and lack of any irritating effects, even when used in comparatively large proportions.
  • the preferred bases are beeswax; water-soluble fats containing a high proportion of synthetic partial glycerides of saturated fatty hydroxyl groups containing acids having 12 to 18 C atoms, preferably in mixture with 50% of triglycerides; the bases disclosed in German Patent No. 1,090,824; the products of US. Patent No. 2,684,970, mixed with glycerol or cetyl alcohol as emollients.
  • the magnesium aspartate is soluble in most cream bases and may be directly incorporated therein. We prefer to prepare a concentrated solution of the magnesium aspartate and admix the solution to the cream base.
  • Example 1 is particularly useful for restoring the smooth texture of skin which has been affected by an excessive use of mascara.
  • the magnesium aspartate may also be used in the form of jellies, whereby any conventional gel such as gelatin, agar-agar, alginates, carrageen, pectin, methyl cellulose may be used.
  • Example 2 Skin lotion Parts Magnesium aspartate 1 Peanut oil, ad 100 Insteadof the peanut oil, we may use other vegetable oils such as olive oil, arachis oil, castor oil, animal oils .such as neats-foot oil, spermaceti; or also mineral oils such as paraffin oil.
  • vegetable oils such as olive oil, arachis oil, castor oil, animal oils .such as neats-foot oil, spermaceti; or also mineral oils such as paraffin oil.
  • a cosmetic preparation containing a cosmetic fatty cream base and incorporated therein about 0.05 to 10 percent by weight of magnesium aspartate, said magnesium aspartate enhancing the skin-softening effect of said cosmetic fatty base.
  • a cosmetic cream comprising an emulsion of oil in water, and from about 0.05% to 10% by weight of magnesium aspartate, said magnesium aspartate enhancing the skin-softening efiect of the cosmetic cream.
  • a cosmetic preparation comprising an oil and about 0.05 to 10 percent by weight of magnesium aspartate dis- References Cited by the Examiner UNITED STATES PATENTS 3,009,859 11/1961 Laborit et a1. 167-68 3,016,334 1/1962 Lewis 16758 3,061,512 10/1962 Anderson et al 1679l S. ROSEN, Primary Examiner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Description

United States Patent Ofi COSMETIC CREAM Hans Alfred Nieper, Aschaffenburg, and Georg Escherich, Melsungen, Hesse, Germany, assignors to Firma Marbert-Kosmetik, Roeber and Sendler, Dusseldorf, Germany No Drawing. Filed June 21, 1961, Ser. No. 118,495 Claims priority, application Germany, July 24, 1958,
N 15,392; Sept. 22, 1958, N 15,614 4 Claims. (Cl. 167-91) The invention relates to cosmetic preparations, particularly to cosmetic creams, and is a continuation-inpart of our application Ser. No. 828,721, filed July 22, 1959, now abandoned.
Cosmetic creams usually comprise emulsion systems of the oil-in-water, or water-in-oil type, or combinations thereof. They are used, for instance, as cold creams or vanishing creams, for smoothing and softening the skin.
We have found that if a small amount of magnesium aspartate (also known as magnesium asparaginate) is added to a cosmetic cream, the properties of the cream are considerably improved as far as the effect on the skin is concerned. Already after short use, the skin becomes much softer and smoother than when ordinary cosmetic creams are used.
Accordingly, a cosmetic cream in accordance with the invention includes about 0.05 to 10 percent by weight of magnesium aspartate.
We believe that the considerable improvement in the properties of a cosmetic cream containing magnesium aspartate is due to the facts that on the one hand, magnesium in form of said salt is only slightly dissociated in the blood and body liquids, passes easily through the cell walls, and then readily exerts its particular effects inside the cell.
The effect of intracellular magnesium consists in an activation of the metabolism ferments of thee esterase type. Such activation improves the growth of the basal layer of the epidermis and produces an increased bonding of intracellular water, increasing the size and tension of the cells.
It appears that the easy migration of the magnesium aspartate through the cell walls is due to the affinity of the aspartic acid to the cells of the epithelial tissue and to the relatively high complex constant of the salt.
The magnesium salt of glutamic acid, which, like aspartic acid, is a dicarboxylic amino acid, does not show the beneficial effect of the magnesium aspartate. A comparison between the complex constants,
wherein Z is the acid anion, shows that K of the magnesium aspartate is 269 and that of magnesium glutamate only 79. However, the complex constant defines only one of a number of useful properties and is by no means alone controlling. This is best seen by a comparison with the magnesium salt of ethylene-diamine tetraacetic acid (Mg=EDTA) which has a complex constant of 5 but has no elfect in cosmetic creams. The probable reason is that the magnesium is replaced at once by other metals, particularly calcium, and is not conveyed into the cells.
The above theoretical considerations are given only as a tentative explanation and are in no way to be construed as limiting the scope of our invention.
'The favorable effects shown by cream bases containing magnesium aspartate on the skin may be reproduced in vitro by tissue cultures.
The classic model for epithelial tissue is the monkey kidney cell monolayer in cultivation flasks. The respira- 3,274,063 Patented Sept. 20, 1966 ice tion rate of both tissues is Q =8 to 10, designating the consumption of mm. of oxygen per mg. of tissue per hour.
For the tests, sterile rhesus kidney cortex tissue treated by Rapaport-trypsination, or hela cells, were suspended 1:400 in a culture medium. A's culture medium, a lactalbumin hydrolysate 0.5% in Hanks salt solution, 10% calf serum added was used.
The test flasks were filled with 90 ml. of the cell containing medium; after 7 days, the culture was treated with 0.2% trypsin solution and then centrifuged. The obtained cell quantity was measure-d in milliliters. The following table gives the results:
The growth tests show that additions of as low as 0.025% of magnesium aspartate increase the cell growth by about percent. An additional advantage of mag* nesium aspartate is its low cost and lack of any irritating effects, even when used in comparatively large proportions.
As cosmetic base, we may use any of the conventional cream bases in form of their oil-in-water or water-in-oil emulsions as they are described, for instance, in Ralph G. Harry Cosmetics, Chemical Publ. Co., New York, 1956, particularly pages 122-123, and in Kirk-Othmer, Encyclopedia of Chemical Technology, vol. 4, pp. 532 et seq.
Among the preferred bases are beeswax; water-soluble fats containing a high proportion of synthetic partial glycerides of saturated fatty hydroxyl groups containing acids having 12 to 18 C atoms, preferably in mixture with 50% of triglycerides; the bases disclosed in German Patent No. 1,090,824; the products of US. Patent No. 2,684,970, mixed with glycerol or cetyl alcohol as emollients.
The magnesium aspartate is soluble in most cream bases and may be directly incorporated therein. We prefer to prepare a concentrated solution of the magnesium aspartate and admix the solution to the cream base.
The following example serves to illustrate the invention, without, however, limiting the same hereto.
Example 1 .-C0ld cream This cream is particularly useful for restoring the smooth texture of skin which has been affected by an excessive use of mascara.
The magnesium aspartate may also be used in the form of jellies, whereby any conventional gel such as gelatin, agar-agar, alginates, carrageen, pectin, methyl cellulose may be used.
3 Example 2.Skin lotion Parts Magnesium aspartate 1 Peanut oil, ad 100 Insteadof the peanut oil, we may use other vegetable oils such as olive oil, arachis oil, castor oil, animal oils .such as neats-foot oil, spermaceti; or also mineral oils such as paraffin oil.
We claim:
1. A cosmetic preparation containing a cosmetic fatty cream base and incorporated therein about 0.05 to 10 percent by weight of magnesium aspartate, said magnesium aspartate enhancing the skin-softening effect of said cosmetic fatty base.
2. A cosmetic cream comprising an emulsion of oil in water, and from about 0.05% to 10% by weight of magnesium aspartate, said magnesium aspartate enhancing the skin-softening efiect of the cosmetic cream.
3. A cosmetic preparation comprising an oil and about 0.05 to 10 percent by weight of magnesium aspartate dis- References Cited by the Examiner UNITED STATES PATENTS 3,009,859 11/1961 Laborit et a1. 167-68 3,016,334 1/1962 Lewis 16758 3,061,512 10/1962 Anderson et al 1679l S. ROSEN, Primary Examiner.
P RANK CACCIAPAGLIA, JR., JULIAN S. LEVI'IT, Examiners.
R. M. GRANIEWSKI, G. A. MENTIS,
Assistant Examiners.

Claims (1)

1. A COSMETIC PREPARATION CONTAINING A COSMETIC FATTY CREAM BASE AND INCORPORED THEREIN ABOUT 0.05 TO 10 PERCENT BY WEIGHT OF MAGNESIUM ASPARATE, SAID MAGNESIUM ASPARTATE ENHANCING THE SKIN-SOFTENING EFFECT OF SAID COSMETIC FATTY BASE.
US118495A 1958-07-24 1961-06-21 Cosmetic cream Expired - Lifetime US3274063A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEN15392A DE1099128B (en) 1958-07-24 1958-07-24 Preparations for the care and promotion of the growth of the skin, hair and nails
DEN15614A DE1131847B (en) 1958-07-24 1958-09-22 Preparations for the care and promotion of the growth of the skin, hair and nails
US82872159A 1959-07-22 1959-07-22

Publications (1)

Publication Number Publication Date
US3274063A true US3274063A (en) 1966-09-20

Family

ID=38544056

Family Applications (1)

Application Number Title Priority Date Filing Date
US118495A Expired - Lifetime US3274063A (en) 1958-07-24 1961-06-21 Cosmetic cream

Country Status (6)

Country Link
US (1) US3274063A (en)
BE (1) BE580575A (en)
CH (1) CH379060A (en)
DE (2) DE1099128B (en)
GB (1) GB937362A (en)
NL (2) NL120093C (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932622A (en) * 1974-01-11 1976-01-13 General Foods Corporation Skin moisturizer
US20030013693A1 (en) * 1998-02-11 2003-01-16 Rtp Pharma Inc. Method and composition for treatment of inflammatory conditions
US20030059484A1 (en) * 1996-11-07 2003-03-27 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US20040086571A1 (en) * 2001-02-22 2004-05-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US7041705B2 (en) 1998-08-19 2006-05-09 Jagotec Ag Injectable aqueous dispersions of propofol
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2932086A1 (en) * 2008-06-06 2009-12-11 Lvmh Rech ANTI-AGE COSMETIC CARE METHOD BY STIMULATING THE EXPRESSION OF SURVIVAL
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US8206746B2 (en) 1996-08-22 2012-06-26 Jagotec Ag Microparticles of water-insoluble substances
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20170056279A1 (en) * 2015-08-25 2017-03-02 Francis Jack Wright Nerve suppression device
US10751267B2 (en) 2016-12-21 2020-08-25 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
US20220313586A1 (en) * 2021-03-31 2022-10-06 L'oreal Cosmetic composition with glaucine, retinol and peptides to combat skin aging
US11540984B2 (en) 2018-05-23 2023-01-03 Conopco, Inc. Nanoemulsions and a method for making the same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154823A (en) * 1976-06-10 1979-05-15 Schutt Steven R Skin treatment compositions and methods of using same
IT8167097A0 (en) * 1981-01-26 1981-01-26 Unilever Nv COSMETIC COMPOSITION FOR THE TREATMENT OF SKIN OR HAIR
US4837012A (en) * 1987-06-19 1989-06-06 S. C. Johnson & Son, Inc. Hair reviver composition containing film-forming amino acids
GB9222772D0 (en) * 1992-10-30 1992-12-09 Unilever Plc Cosmetic composition
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5962523A (en) * 1996-10-25 1999-10-05 Discovery Laboratories, Inc. Methods of using butyric acid derivatives to protect against hair loss
GB9622659D0 (en) * 1996-10-31 1997-01-08 Unilever Plc Hair treatment composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009859A (en) * 1958-07-22 1961-11-21 Laborit Henri Potassium aspartate and magnesium aspartate fatigue-recovery promoting process and compositions
US3016334A (en) * 1958-11-24 1962-01-09 Thomas J Lewis Skin cream containing low gel strength, low viscosity gelatin
US3061512A (en) * 1959-06-25 1962-10-30 Borden Co Dermatological preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2032042A (en) * 1934-06-30 1936-02-25 Northam Warren Corp Fingernail polish remover
US2719811A (en) * 1945-10-01 1955-10-04 Inst Divi Thomae Foundation Means for controlling the respiration of animal cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009859A (en) * 1958-07-22 1961-11-21 Laborit Henri Potassium aspartate and magnesium aspartate fatigue-recovery promoting process and compositions
US3016334A (en) * 1958-11-24 1962-01-09 Thomas J Lewis Skin cream containing low gel strength, low viscosity gelatin
US3061512A (en) * 1959-06-25 1962-10-30 Borden Co Dermatological preparation

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932622A (en) * 1974-01-11 1976-01-13 General Foods Corporation Skin moisturizer
US20040018229A1 (en) * 1995-10-17 2004-01-29 Henriksen Inge B. Insoluble drug delivery
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6974593B2 (en) 1995-10-17 2005-12-13 Jagotec Ag Insoluble drug delivery
US8206746B2 (en) 1996-08-22 2012-06-26 Jagotec Ag Microparticles of water-insoluble substances
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US20030059484A1 (en) * 1996-11-07 2003-03-27 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US7678380B2 (en) * 1996-11-07 2010-03-16 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US20090297639A1 (en) * 1996-11-07 2009-12-03 Lvmh Recherche Cosmetic treatement method for fighting against skin ageing effects
US20030013693A1 (en) * 1998-02-11 2003-01-16 Rtp Pharma Inc. Method and composition for treatment of inflammatory conditions
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US7041705B2 (en) 1998-08-19 2006-05-09 Jagotec Ag Injectable aqueous dispersions of propofol
US7097849B2 (en) 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US7939106B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US8703202B2 (en) 2000-09-20 2014-04-22 Jagotec Ag Coated tablets
US20040086571A1 (en) * 2001-02-22 2004-05-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20100040706A1 (en) * 2008-06-06 2010-02-18 Lvmh Recherche Method of anti-ageing cosmetic care by stimulation of survivin expression
FR2932086A1 (en) * 2008-06-06 2009-12-11 Lvmh Rech ANTI-AGE COSMETIC CARE METHOD BY STIMULATING THE EXPRESSION OF SURVIVAL
US20170056279A1 (en) * 2015-08-25 2017-03-02 Francis Jack Wright Nerve suppression device
US10751267B2 (en) 2016-12-21 2020-08-25 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US10980718B2 (en) 2016-12-21 2021-04-20 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
US11596586B2 (en) 2016-12-21 2023-03-07 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11666519B2 (en) 2016-12-21 2023-06-06 Conopco, Inc. Personal care compositions with cystine
US11759412B2 (en) 2016-12-21 2023-09-19 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11540984B2 (en) 2018-05-23 2023-01-03 Conopco, Inc. Nanoemulsions and a method for making the same
US20220313586A1 (en) * 2021-03-31 2022-10-06 L'oreal Cosmetic composition with glaucine, retinol and peptides to combat skin aging

Also Published As

Publication number Publication date
CH379060A (en) 1964-06-30
NL120093C (en)
GB937362A (en) 1963-09-18
BE580575A (en) 1960-01-11
DE1099128B (en) 1961-02-09
NL241476A (en)
DE1131847B (en) 1962-06-20

Similar Documents

Publication Publication Date Title
US3274063A (en) Cosmetic cream
CN1933805B (en) Cosmetic or dermopharmaceutical medicine for reducing wrinkle because of age
JPS63192703A (en) External agent for skin
JPH07196469A (en) Cosmetics composition for care of composite skin
US3536816A (en) Water-in-oil emulsion
US3574854A (en) Method for soothing the skin with a cream containing sodium chloride
EP0084341B1 (en) Emulsion-type composition for external use
WO2000004047A1 (en) Cosmetic compositions for slimming
JP3607062B2 (en) Fat accumulation inhibitor and skin external preparation containing the same
JPS5826726B2 (en) Keshiyouriyo
US2294229A (en) Cosmetic preparations
JPH10182347A (en) Skin cosmetic
US4107333A (en) Skin care with a cosmetic composition containing oleyl acetate
Walker et al. Influence of alcohol on collagen synthesis in vitro
JPS62120308A (en) Cosmetic
US2771394A (en) Hair grooming preparation
JPH0521085B2 (en)
US2520980A (en) Cosmetic creams
JP3262780B2 (en) Phytosphingosine aqueous solution, its production and use
JPS6127908A (en) Preventive for chapping
SU992058A1 (en) Agent for artificial sun-tan
US1073787A (en) Cosmetic cream.
JPH04108721A (en) Cell-activation agent composition
CN108379212A (en) Newborn moisturizing cream of a kind of camel with senile-resistant efficacy and preparation method thereof
JPS6256132B2 (en)